Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics

참고문헌 (203)

1. Linsley, P. S., "CTLA-4 is a second receptor for the B cell activation antigen B7", J. Exp. Med, 174, pp.561~569 (1991)
2. Xing, C., "The roles of exosomal immune checkpoint proteins in tumors", Mil. Med. Res, 8, pp.56~ (2021)
3. Gaikwad, S., "Immune checkpoint proteins : Signaling mechanisms and molecular interactions in cancer immunotherapy", Semin. Cancer Biol, 86, pp.137~150 (2022)
4. Weber, J., "Immune checkpoint proteins : a new therapeutic paradigm for cancer preclinical background : CTLA-4 and PD-1 blockade", Semin. Oncol, 37, pp.430~439 (2010)
5. He, X., "Immune checkpoint signaling and cancer immunotherapy", Cell Res, 30, pp.660~669 (2020)
6. Ribas, A., "Cancer immunotherapy using checkpoint blockade", Sci. (N. Y., NY), 359, pp.1350~1355 (2018)
7. Hodi, F. S., "Improved survival with ipilimumab in patients with metastatic melanoma", N. Engl. J. Med, 363, pp.711~723 (2010)
8. Beaver, J. A., "Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression : a US Food and Drug Administration pooled ana lysis", Lancet Oncol, 19, pp.229~239 (2018)
9. Heidegger, S., "Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy", Cell Rep. Med, 4, pp.101171~ (2023)
10. Wang, A., "Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment", Biochimica et biophysica acta Reviews on cancer, pp.189058~ (2023)
11. Fang, J., "Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment : new insights and therapeutic implications", Cell Death Dis, 14, pp.586~ (2023)
12. Ye, Z., "Tissue-derived extracellular vesicles in cancer progression: mechanisms, roles, and potential applications", Cancer Metastasis Rev (2023)
13. Théry, C., "Minimal information for studies of extracellular vesicles 2018(MISEV2018) : a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines", J. Extracell. vesicles, 7, pp.1535750~ (2018)
14. Guo, S., "The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis", Mol. Cancer, 22, pp.193~ (2023)
15. Yue, M., "Extracellular vesicles remodel tumor environment for cancer immunotherapy", Mol. Cancer, 22, pp.203~ (2023)
16. Alia Moosavian, S., "Melanoma-derived exosomes : Versatile extracellular vesicles for diagnosis, metastasis, immune modulation, and treatment of melanoma", Int. Immuno pharmacol, 113, pp.109320~ (2022)
17. Fyfe, J., "Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity", Semin. Cancer Biol, 96, pp.36~47 (2023)
18. Li, L., "Exosomes as a modulator of immune resistance in human cancers", Cytokine Growth Factor Rev, 73, pp.135~149 (2023)
19. Wang, H., "High throughput and noninvasive exosomal PD-L1 detection for accurate immunotherapy response prediction via Tim4-functionalized magnetic core-shell metal-organic frameworks", Anal. Chem, 95, pp.18268~18277 (2023)
20. Park, S. J., "Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer", BMC cancer, 23, pp.389~ (2023)
21. Xu, P., "Clinical significance of plasma PD-L1(+)exosomes in the manage ment of diffuse large B cell lymphoma", Ann. Hematol, 102, pp.2435~2444 (2023)
22. Wang, K., "Melatonin enhances anti-tumor immunity by targeting macro phages PD-L1 via exosomes derived from gastric cancer cells", Mol. Cell. Endo crinol, 568-569, pp.111917~ (2023)
23. Li, J., "Exosomes-delivered PD-L1 siRNA and CTLA-4 siRNA protect against growth and tumor immune escape in colorectal cancer", Genomics, 115, pp.110646~ (2023)
25. Akhtar, M., "PD-L1 immunostaining : what pathologists need to know", Diagnostic Pathol, 16, pp.94~ (2021)
26. Akinleye, A., "Immune checkpoint inhibitors of PD-L1 as cancer therapeutics", J. Hematol. Oncol, 12, pp.92~ (2019)
27. Chamoto, K., "Insights from a 30-year journey : function, regulation and therapeutic modulation of PD1", Nat. Rev. Immunol, 23, pp.682~695 (2023)
28. Glaviano, A., "PI3K", AKT, Mol. Cancer, pp.2023, 22[DOI]
29. Xu, W., "Exosomal PIK3CB promotes PD L1 expression and malignant transformation in esophageal squamous cell car cinoma", Med. Oncol. (Northwood, Lond., Engl.), 40, pp.221~ (2023)
30. Xu, D., "Tumor-derived small extracellular vesicles promote breast cancer progression by upregulating PD-L1 expression in macrophages", Cancer cell Int, 23, pp.137~ (2023)
31. Zhao, L., "LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1", PD-L1 Axis, 2024, pp.47, 64~76
32. Han, N., "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1", JAK1, Oral. Oncol, pp.2023, 145[DOI]
33. Lütge, M., "Differentiation and activation of fibroblastic reticular cells", Immunological Rev, 302, pp.32~46 (2021)
34. Yin, L., "Extracellular vesicles derived from M2-polarized tumor-asso ciated macrophages promote immune escape in ovarian cancer through NEAT1", miR-101-3p, PD-L1 axis, pp.Cancer Immunol., Immunother. : CII, 2023[DOI]
35. Wang, Q. M., "Exosomal lncRNA NEAT1 inhibits NK cell activity to promote multiple myeloma cell immune escape via an EZH2", PBX1 axis, 2023, ~
36. Yang, K., "Exosomal circEIF3K from cancer-associated fibro blast promotes colorectal cancer(CRC)progression via miR-214", PD-L1 axis, 2021, pp.21, 933~
37. Zhao, B., "Lnc-CCNH-8 promotes immune escape by up-regulating PD-L1 in hepatocellular carcinoma", Mol. Ther. Nucleic acids, 35, pp.102125~ (2024)
38. Cubillos-Ruiz, J. R., "Tumorigenic and immuno suppressive effects of endoplasmic reticulum stress in cancer", Cell, 168, pp.692~706 (2017)
39. Fu, X., "Endoplasmic reticulum stress, cell death and tumor : association between endoplasmic reticulum stress and the apoptosis pathway in tumors(Review)", Oncol. Rep, 45, pp.801~808 (2021)
40. Yuan, Y., "Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polar ization", Cell Commun. Signal, 20, pp.12~ (2022)
41. Yan, D., "STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1α activation", Cell Rep, 16, pp.2914~2927 (2016)
42. Liu, J., "Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages", Hepatol. (Baltim., Md), 70, pp.241~258 (2019)
43. Li, X., "Reactive oxygen species reprogram macrophages to suppress anti tumor immune response through the exosomal miR-155-5p", PD-L1 pathway, 2022, pp.41, 41~
44. Yuan, Y., "Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8(+)T cells", Cancer Lett, 500, pp.98~106 (2021)
45. Liu, J., "Extracellular vesicle PD-L1 in reshaping tumor immune micro environment : biological function and potential therapy strategies", Cell Commun. Signal, 20, pp.14~ (2022)
46. Hsu, J. M., "STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion", Nat. Commun, 9, pp.1908~ (2018)
47. Okada, M., "Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells", Cell Rep, 20, pp.1017~1028 (2017)
48. Li, C. W., "Glycosylation and stabilization of programmed death ligand-1suppresses T-cell activity", Nat. Commun, 7, pp.12632~ (2016)
49. Zhu, L., "Quantification-promoted discovery of glycosylated exosomal PD-L1as a potential tumor biomarker", Small methods, 6, pp.e2200549~ (2022)
50. Zhu, L., "Coupling aptamer-based protein tagging with metabolic glycan labeling for in situ visualization and biological function study of exosomal protein-specific glycosylation", Angew. Chem. (Int. ed. Engl.), 60, pp.18111~18115 (2021)
51. Sun, W., "Tumor stem cell-derived exosomal microRNA-17-5p inhibits anti tumor immunity in colorectal cancer via targeting SPOP and overexpressing PD L1", Cell death Discov, 8, pp.223~ (2022)
52. Gou, Q., "PD-L1 degradation pathway and immunotherapy for cancer", Cell death Dis, 11, pp.955~ (2020)
53. Xian, D., "LncRNA KCNQ1OT1 secreted by tumor cell derived exosomes mediates immune escape in colorectal cancer by regulating PD-L1 Ubiquitination via MiR-30a-5p", USP22, 2021, pp.9, 653808~
54. Jing, H., "Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity", J. investigative Med. : Off. Publ. Am. Federation Clin. Res, 72, pp.57~66 (2024)
55. Alam, M. R., "The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy", Genes Dis, 11, pp.321~334 (2024)
56. Wei, F., "Exosomal PD-L1 derived from head and neck squamous cell car cinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage", Oral. Oncol, 145, pp.106532~ (2023)
57. Tang, Y., "The biogenesis, biology, and clinical significance of exosomal PD L1 in cancer", Front. Immunol, 11, pp.604~ (2020)
58. Yang, Y., "Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth", Cell Res, 28, pp.862~864 (2018)
59. Xu, R., "Extracellular vesicles in cancer-implications for future improve ments in cancer care", Nat. Rev. Clin. Oncol, 15, pp.617~638 (2018)
60. Chen, J., "GOLM1 exacerbates CD8(+)T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages", Signal Transduct. Target. Ther, 6, pp.397~ (2021)
61. Ye, Z., "Manipulation of PD-L1 endosomal trafficking promotes anticancer immunity", Adv. Sci. (Weinh., Baden.-Wurtt., Ger.), 10, pp.e2206411~ (2023)
62. Shen, D. D., "LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer", Mol. cancer, 21, pp.75~ (2022)
63. Gu, H., "Sorting protein VPS33B regulates exosomal autocrine signaling to mediate hematopoiesis and leukemogenesis", J. Clin. Investig, 126, pp.4537~4553 (2016)
64. Villarroya-Beltri, C., "ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins", Nat. Commun, 7, pp.13588~ (2016)
65. Kanemoto, S., "Multivesicular body formation enhancement and exosome release during endoplasmic reticulum stress", Biochemical biophysical Res. Com mun, 480, pp.166~172 (2016)
66. Gurung, S., "The exosome journey : from biogenesis to uptake and intracellular signalling", Cell Commun. Signal. : CCS, 19, pp.47~ (2021)
67. Liu, D. A., "A phosphoinositide switch mediates exocyst recruitment to multivesicular endosomes for exosome secretion", Nat. Commun, 14, pp.6883~ (2023)
68. Xiang, J., "Exo70 Promotes the invasion of pancreatic cancer cells via the regulation of exosomes", Cancers, 16 (2024)
69. Izquierdo, E., "Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies", Blood, 139, pp.3617~3629 (2022)
70. Yu, X., "The regulation of exosome secretion : a novel function of the p53 protein", Cancer Res, 66, pp.4795~4801 (2006)
71. Wang, J., "Helicobacter pylori CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes", iScience, 26, pp.108414~ (2023)
72. Qiu, Y., "Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer", Oncogene, 40, pp.4992~5001 (2021)
73. Xu, R., "Aptamer-Assisted Traceless Isolation of PD-L1-Positive Small Extra cellular Vesicles for Dissecting Their Subpopulation Signature and Function", Anal. Chem, 95, pp.1016~1026 (2023)
74. Wang, J., "Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients", J. nanobiotechnology, 18, pp.151~ (2020)
75. Lin, W., "Extracellular vesicle-cell adhesion molecules in tumours : biofunc tions and clinical applications", Cell Commun. Signal. : CCS, 21, pp.246~ (2023)
76. Zhang, W., "ICAM-1-mediated adhesion is a prerequisite for exosome induced T cell suppression", Developmental cell, 57, pp.329~343 (2022)
77. Wang, R., "The detection of exosomal PD-L1 in peripheral blood", Methods Mol. Biol. (Clifton, NJ), 2695, pp.195~212 (2023)
78. Feng, R., "Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape of bladder cancer via PD-L1", PD-1 expression, 2023, pp.23, 1410~1420
79. Yu, Z. L., "Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns", NPJ Precis. Oncol, 6, pp.42~ (2022)
80. Ko, H. H., "Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma", Cancer Sci, 114, pp.3857~3872 (2023)
81. Ou, Q., "Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival", Cell tissue Res, 389, pp.465~481 (2022)
82. Wang, B., "Mutual regulation of PD-L1 immunosuppression between tumor associated macrophages and tumor cells : a critical role for exosomes", Cell Commun. Signal, 22, pp.21~ (2024)
83. Schroeder, J. C., "Circulating exosomes inhibit B cell proliferation and activity", Cancers, 12 (2020)
84. Chen, Y., "Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1", Front. Pharmacol, 14, pp.1159829~ (2023)
85. Poggio, M., "Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory", Cell, 177, pp.414~427 (2019)
86. Li, D., "Prostate cancer cells synergistically defend against CD8(+)T cells by secreting exosomal PD-L1", Cancer Med, 12, pp.16405~16415 (2023)
87. Ma, J., "Exosomes released from PD-L1(+)tumor associated macrophages promote peritoneal metastasis of epithelial ovarian cancer by up-regulating T cell lipid metabolism", Biochem. biophysics Rep, 36, pp.101542~ (2023)
88. Yin, Z, "Mechanisms underlying low-clinical responses to PD-1", PD-L1blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1, 2021, pp.9, ~
89. Chen, G., "Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response", Nature, 560, pp.382~386 (2018)
90. Theodoraki, M. N., "Clinical Significance of PD-L1(+)Exosomes in Plasma of Head and Neck Cancer Patients", Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res, 24, pp.896~905 (2018)
91. Chen, J., "Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1", Cell. Mol. Immunol, 19, pp.1290~1301 (2022)
92. Gong, B., "Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer", J. Exp. Med, 216, pp.982~1000 (2019)
93. Serratì, S., "Circulating extracellular vesicles expressing PD1 and PD-L1predict response and mediate resistance to checkpoint inhibitors immu notherapy in metastatic melanoma", Mol. cancer, 21, pp.20~ (2022)
94. Affolter A, "Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes", International journal of oncology, 63 (2023)
95. Zheng, Y., "Glioblastoma stem cell(GSC)-derived PD-L1-containing exo somes activates AMPK", ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma, 2021, pp.11, 63~
96. Rudd, C. E., "CD28 and CTLA-4 coreceptor expression and signal transduction", Immunological Rev, 229, pp.12~26 (2009)
97. Koni, M., "Circulating extracellular vesicles derived from tumor endothelial cells hijack the local and systemic anti-tumor immune response : Role of mTOR", G-CSF pathway, 2023, pp.195, 106871~
98. Weng, H. P., "Canine diffuse large b-cell lymphoma downregulates the activity of CD8 +T-cells through tumor-derived extracellular vesicles", Cancer cell Int, 23, pp.252~ (2023)
99. Ukrainskaya, V. M., "CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality", Sci. Rep, 13, pp.463~ (2023)
100. Walker, L. S. K., "The link between circulating follicular helper T cells and auto immunity", Nat. Rev. Immunol, 22, pp.567~575 (2022)
101. Li, Z., "Esophageal cancer cell-derived small extracellular vesicles decrease circulating Tfh", Tfr via sEV-PDL1 to promote immunosuppression, 2023, pp.72, 4249~4259
102. Oyewole-Said, D., "Beyond T-Cells : Functional Characterization of CTLA-4Expression in Immune and Non-Immune Cell Types", Front. Immunol, 11, pp.608024~ (2020)
103. Liu, L., "Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma via the miRNA-4474-3P-ALOX-15 and EMT axes", Biosci. trends, 16, pp.267~281 (2022)
104. Mondal, S. K., "Small EV in plasma of triple negative breast cancer patients induce intrinsic apoptosis in activated T cells", Commun. Biol, 6, pp.815~ (2023)
105. Benecke, L, "Exosomes: Small EVs with Large Immunomodulatory Effect in Glioblastoma", International journal of molecular sciences, 22 (2021)
106. Wang, Y., "Exosome CTLA-4 Regulates PTEN", CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepa tocellular Carcinoma, 2021, pp.12, 757194~
107. Wolf, Y., "TIM3 comes of age as an inhibitory receptor", Nat. Rev. Immunol, 20, pp.173~185 (2020)
108. Cai, L., "Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy", J. Hematol. Oncol, 16, pp.101~ (2023)
109. Chiba, S., "Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1", Nat. Immunol, 13, pp.832~842 (2012)
110. Ndhlovu, L. C., "Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity", Blood, 119, pp.3734~3743 (2012)
111. Clayton, K. L., "T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases", J. Immunol. (Baltim., Md : 1950), 192, pp.782~791 (2014)
112. Lefebvre, A., "Extracellular vesicles derived from nasopharyngeal carcinoma induce the emergence of mature regulatory dendritic cells using a galectin-9dependent mechanism", J. Extracell. vesicles, 12, pp.e12390~ (2023)
113. de Mingo Pulido, Á., "The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extra cellular DNA uptake", Immunity, 54, pp.1154~1167 (2021)
114. Zhang, C. X., "Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation", Oncogenesis, 9, pp.65~ (2020)
115. Wu, J., "Exosomes in malignant pleural effusion from lung cancer patients impaired the cytotoxicity of double-negative T cells", Transl. Oncol, 27, pp.101564~ (2023)
116. Javadi, J., "Diagnostic and prognostic utility of the extracellular vesicles subpopulations present in pleural effusion", Biomolecules, 11 (2021)
117. Li, X., "TIM-3 shuttled by MV3 cells-secreted exosomes inhibits CD4(+)T cell immune function and induces macrophage M2polarization to promote the growth and metastasis of melanoma cells", Transl. Oncol, 18, pp.101334~ (2022)
118. Cheng, Z., "Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through Tim-3", Arch. Med. Res, 52, pp.200~210 (2021)
119. Andrews, L. P., "Molecular pathways and mechanisms of LAG3 in cancer therapy", Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res, 28, pp.5030~5039 (2022)
120. Aggarwal, V., "LAG-3 as the third checkpoint inhibitor", Nat. Immunol, 24, pp.1415~1422 (2023)
121. Hao, Y., "Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-βsignaling", Front. Med (2023)
122. Yan, G., "Potential impact of ALKBH5 and YTHDF1 on tumor immunity in colon adenocarcinoma", Front. Oncol, 11, pp.670490~ (2021)
123. Ning, J., "METTL3 inhibition induced by M2 macrophage-derived extra cellular vesicles drives anti-PD-1 therapy resistance via M6A-CD70-mediated immune suppression in thyroid cancer", Cell death Differ, 30, pp.2265~2279 (2023)
124. Wang, J., "Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3", Cell, 176, pp.334~347 (2019)
125. Maruhashi, T., "Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity", Immunity, 55, pp.912~924 (2022)
126. Zhang, Y., "FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response", Clinical and experi mental immunology (2023)
127. Kouo, T., "Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells", Cancer Immunol. Res, 3, pp.412~423 (2015)
128. Yakubovich, E., "Mesenchymal ovarian cancer cells promote CD8(+)T cell exhaustion through the LGALS3LAG3 axis", NPJ Syst. Biol. Appl, 9, pp.61~ (2023)
129. Cela, I., "LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma", Oral diseases (2023)
130. Mortezaee, K., "Alternative immune checkpoints in immunor egulatory profile of cancer stem cells", Heliyon, 9, pp.e23171~ (2023)
131. Shi, J., "Molecular characteristics of single patient-derived glioma stem-like cells from primary and recurrent glioblastoma", Anti-cancer drugs, 33, pp.e381~e388 (2022)
132. Solinas, C., "The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy", ESMO Open, 5 (2020)
133. Borgeaud, M., "Novel targets for immune-checkpoint inhibition in cancer", Cancer Treat. Rev, 120, pp.102614~ (2023)
134. Fan, X., "Exosome miR-27a-3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma", Thorac. cancer, 11, pp.1453~1464 (2020)
135. Stone, E. L., "ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation", Immunity, 42, pp.239~251 (2015)
136. Sage, P. T., "The receptor PD-1controls follicular regulatory T cells in the lymph nodes and blood", Nat. Immunol, 14, pp.152~161 (2013)
137. Saliba, D. G., "Composition and structure of synaptic ectosomes exporting antigen receptor linked to functional CD40 ligand from helper T cells", eLife, 8 (2019)
138. Jiang, F., "Extracellular vesicle-derived protein file from peripheral blood predicts immune-related adverse events in gastric cancer patients receiving immunotherapy", Cancers, 14 (2022)
139. Carthon, B. C., "Preoperative CTLA-4 blockade : tolerability and immune monitoring in the setting of a presurgical clinical trial", Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res, 16, pp.2861~2871 (2010)
140. Koyama, S., "Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints", Nat. Commun, 7, pp.10501~ (2016)
141. Dulal, D., "Tackling of immunorefractory tumors by targeting alternative immune checkpoints", Cancers, 15 (2023)
142. Lu, H., "B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3", ULBP2 axis, 2021, pp.70, 1213~1226
143. Purvis, I. J., "B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role", Int. J. Mol. Sci, 21 (2020)
144. Wu, R., "Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1", mTOR, Cell. Signal, pp.2023, 109[DOI]
145. Picarda, E., "Molecular pathways: targeting B7-H3(CD276) for human cancer immunotherapy", Clin. Cancer Res: Off. J. Am. Assoc. Cancer Res, 22, pp.3425~3431 (2016)
146. Joller, N., "LAG-3, TIM-3, and TIGIT : Distinct functions in immune regulation", Immunity, 57, pp.206~222 (2024)
147. Swatler, J., "4-1BBL-containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells", Blood Adv, 6, pp.1879~1894 (2022)
148. Holmgaard, R. B., "Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner", Cell Rep, 13, pp.412~424 (2015)
149. Akbar, S., "Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1", PD L1 therapy in non-small cell lung cancer patients, 2022, pp.13, 1097117~
150. Jung, M. Y., "Superinduction of immunosuppressive glioblastoma extra cellular vesicles by IFN-γ through PD-L1 and IDO1", Neuro-Oncol. Adv, 4, pp.vdac017~ (2022)
151. Ying, X., "Kynurenine in IDO1(high)cancer cell-derived extracellular vesicles promotes angiogenesis by inducing endo thelial mitophagy in ovarian cancer", J. Transl. Med, 22, pp.267~ (2024)
152. Burova, E., "Preclinical development of the anti-LAG-3 antibody REGN3767 : characterization and activity in combination with the anti-PD-1 antibody cemiplimab in human PD-1xLAG-3-Knockin mice", Mol. Cancer Therapeutics, 18, pp.2051~2062 (2019)
153. Euvrard, R., "Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis", Fundamental Clin. Pharmacol (2023)
154. Yoo, W. S., "Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta analysis and comprehensive review", Endocrinol. Metab. (Seoul., Korea), 38, pp.750~759 (2023)
155. Vardarli, I, "Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials", The Journal of clinical endocrinology and metabolism (2023)
156. Cristescu, R., "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy", Science (New York, NY), 362 (2018)
157. Rayamajhi, S., "Extracellular Vesicles as Liquid Biopsy Biomarkers across the Cancer Journey : From Early Detection to Recurrence", Clin. Chem, 70, pp.206~219 (2024)
158. Wang, Y., "Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients", Clin. Exp. Immunol, 208, pp.316~322 (2022)
159. Eslami, S. Z., "Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer", Br. J. Cancer (2023)
160. Shen, B., "PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma", Br. J. cancer, 122, pp.640~647 (2020)
161. Tran, L., "Cisplatin Alters Antitumor Immunity and Synergizes with PD-1", PD L1 Inhibition in Head and Neck Squamous Cell Carcinoma, 2017, pp.5, 1141~1151
162. Rong, Q. X., "GM-CSF mediates immune evasion via upregulation of PD-L1expression in extranodal natural killer", T cell lymphoma, 2021, pp.20, 80~
163. Li, J. W., "Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma", Oncoimmunology, 10, pp.1995166~ (2021)
164. Zhang, Q., "Comprehensive isolation of extracellular vesicles and nanoparticles", Nat. Protoc, 18, pp.1462~1487 (2023)
165. Gorgzadeh, A., "A state-of-the-art review of the recent advances in exosome isolation and detection methods in viral infection", Virol. J, 21, pp.34~ (2024)
166. Wang, C., "Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling", ACS Sens, 6, pp.3308~3319 (2021)
167. Wang, Y., "Rapid and sensitive detection of PD-L1 exosomes using Cu-TCPP 2D MOF as a SPR sensitizer", Biosens. Bioelectron, 201, pp.113954~ (2022)
168. Huang, M., "Homogeneous, Low-volume, Efficient, and Sensitive Quan titation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immu notherapy Response Prediction", Angew. Chem. (Int. ed. Engl.), 59, pp.4800~4805 (2020)
169. Lin, B., "Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR", Angew. Chem. (Int. ed. Engl.), 60, pp.7582~7586 (2021)
170. Qin, X., "Simultaneous detection of cancerous exosomal miRNA-21 and PD L1 with a sensitive dual-cycling nanoprobe", Biosens. Bioelectron, 216, pp.114636~ (2022)
171. Chang, L., "Microporous PdCuB nanotag-based electrochemical aptasensor with Au@CuCl(2)nanowires interface for ultrasensitive detection of PD-L1positive exosomes in the serum of lung cancer patients", J. nanobiotechnology, 21, pp.86~ (2023)
172. Pang, Y., "Personalized detection of circling exosomal PD-L1 based on Fe(3)O(4)@TiO(2)isolation and SERS immunoassay", Biosens. Bioelectron, 148, pp.111800~ (2020)
173. Fan, Z., "Accurate and rapid quantification of PD-L1 positive exosomes by a triple-helix molecular probe", Analytica Chim. acta, 1251, pp.340984~ (2023)
174. Erman, A., "The prognostic and predictive value of human gastrointestinal microbiome and exosomal mRNA expression of PD-L1 and IFNγ for immune checkpoint inhibitors response in metastatic melanoma patients: PROTOCOL TRIAL", Biomedicines, 11 (2023)
175. Wang, J., "Circulating exosomal PD-L1 at initial diagnosis predicts outcome and survival of patients with osteosarcoma", Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res, 29, pp.659~666 (2023)
176. Qiu, P., "Characterization of exosome-related gene risk model to evaluate the tumor immune microenvironment and pre dict prognosis in triple-negative breast cancer", Front. Immunol, 12, pp.736030~ (2021)
177. Su, D., "A prognostic exosome-related LncRNA risk model correlates with the immune microenvironment in liver cancer", Front. Genet, 13, pp.965329~ (2022)
178. Gao, J., "Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer", Biochem. Biophys. Res. Commun, 498, pp.409~415 (2018)
179. Zhang, P. F., "Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma", Mol. Cancer, 19, pp.110~ (2020)
180. Liu, L., "MicroRNA-15a carried by mesenchymal stem cell-derived extra cellular vesicles inhibits the immune evasion of colorectal cancer cells by regulating the KDM4B", HOXC4, Front. Cell Dev. Biol, pp.2021, 9[DOI]
181. Chen, H. L., "Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adeno carcinoma by regulating PD-L1 expression", Cancer Med, 11, pp.2627~2643 (2022)
182. Shin, J. M., "Sulfisoxazole elicits robust antitumour immune response along with immune checkpoint therapy by inhibiting exosomal PD-L1", Adv. Sci. (Weinh., Baden.-Wurtt., Ger.), 9, pp.e2103245~ (2022)
183. Kim, G. B., "Harnessing oncolytic extracellular vesicles for tumor cell preferential cytoplasmic delivery of misfolded proteins for cancer immu notherapy", Small (Weinh. der Bergstr., Ger.), 19, pp.e2300527~ (2023)
184. Im, E. J., "Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A", Nat. Commun, 10, pp.1387~ (2019)
185. Lee, C. H., "Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1", Theranostics, 12, pp.1971~1987 (2022)
186. Ye, H., "In situ sprayed nanovaccine suppressing exosomal PD-L1 by golgi apparatus disorganization for postsurgical melanoma immunotherapy", ACS nano, 17, pp.10637~10650 (2023)
187. Lallemand, T., "nSMase2(Type 2-Neutral Sphingomyelinase)deficiency or inhibition by GW4869 reduces inflammation and atherosclerosis in Apoe(-", -)mice, 2018, pp.38, 1479~1492
188. Takahashi, A., "Exosomes maintain cellular homeostasis by excreting harmful DNA from cells", Nat. Commun, 8, pp.15287~ (2017)
189. Deng, J., "Overcoming the resistance of hepatocellular carcinoma to PD 1", PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles, 2023, pp.12, 2152635~
190. Lee, J., "Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy", Front. Oncol, 13, pp.1233376~ (2023)
191. Chang, C., "Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma", Cancer Immunol., Immunother. CII, 72, pp.3727~3738 (2023)
192. Veerman, R. E., "Antigen-loaded extracellular vesicles induce responsiveness to anti-PD-1 and Anti-PD-L1 treatment in a checkpoint refractory melanoma model", Cancer Immunol. Res, 11, pp.217~227 (2023)
193. Zhang, Y., "Complete remission of tumors in mice with neoantigen-painted exosomes and anti-PD-1 therapy", Mol. Ther. : J. Am. Soc. Gene Ther, 31, pp.3579~3593 (2023)
194. Cifuentes-Rius, A., "Inducing immune tolerance with dendritic cell-targeting nanomedicines", Nat. Nano technol, 16, pp.37~46 (2021)
195. Phung, C. D., "Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses", Acta Biomater, 115, pp.371~382 (2020)
196. Liu, Y., "Mesenchymal stromal", stem cell tissue source and in vitro expansion impact extracellular vesicle protein and miRNA com positions as well as angiogenic and immunomodulatory capacities, 2024, pp.13, e12472~
197. Zhao, L., "LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1", PD-L1 Axis, 2023, ~
198. Zheng, Y., "Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma", J. cell Commun. Signal, 14, pp.389~402 (2020)
199. Yin, Y., "Colorectal cancer-derived small extracellular vesicles promote tumor immune evasion by upregulating PD-L1 expression in tumor-associated macrophages", Adv. Sci. (Weinh., Baden.-Wurtt., Ger.), 9, pp.2102620~ (2022)
200. Rabe, D. C., "Tumor extracellular vesicles regulate macrophage-driven metastasis through CCL5", Cancers, 13 (2021)
201. Zhang, C., "Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28", Front. Oncol, 10, pp.760~ (2020)
202. Shimada, Y., "Serum-derived exosomal PD-L1 expression to predict anti-PD 1 response and in patients with non-small cell lung cancer", Sci. Rep, 11, pp.7830~ (2021)
203. Hao, J., "Homogeneous, simple, and direct analysis of exosomal PD-L1 via aptamer-bivalent-cholesterol-anchor assembly of DNAzyme(ABCzyme)for tumor immunotherapy", Anal. Chem, 95, pp.6854~6862 (2023)

관련 논문AI추천